Over the last 7 days, the United States market has remained flat, yet it is up 32% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and scalability in a rapidly evolving sector.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Super Micro Computer |
23.83% |
24.32% |
★★★★★★ |
|
Ardelyx |
25.24% |
69.64% |
★★★★★★ |
|
Sarepta Therapeutics |
24.00% |
42.49% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
22.35% |
70.33% |
★★★★★★ |
|
Clene |
78.50% |
60.16% |
★★★★★★ |
|
TG Therapeutics |
34.66% |
56.98% |
★★★★★★ |
|
Alkami Technology |
21.89% |
98.60% |
★★★★★★ |
|
Travere Therapeutics |
31.70% |
72.51% |
★★★★★★ |
|
Seagen |
22.57% |
71.80% |
★★★★★★ |
|
ImmunoGen |
26.00% |
45.85% |
★★★★★★ |
Click here to see the full list of 247 stocks from our US High Growth Tech and AI Stocks screener.
We’ll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★★★
Overview: Blueprint Medicines Corporation is a precision therapy company that develops medicines for genomically defined cancers and blood disorders, with a market cap of $6.12 billion.
Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to $434.42 million. As a precision therapy developer, it focuses on creating treatments for genomically defined cancers and blood disorders both in the U.S. and internationally.
Blueprint Medicines, amid a challenging landscape, has shown remarkable resilience with its revenue surging by 25.5% annually, outpacing the US market’s growth of 8.9%. This growth trajectory is supported by significant R&D investments that underscore its commitment to innovation in tackling complex diseases. The firm’s recent adjustment in revenue guidance to $475-$480 million for AYVAKIT reflects a robust demand and operational excellence. Despite current unprofitability, Blueprint is poised for profitability within three years with earnings expected to grow at an impressive rate of 68.6% per year, highlighting its potential in transforming patient outcomes through scientific breakthroughs.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market capitalization of approximately $10.02 billion.
Operations: Roku generates revenue primarily through its Platform segment, which accounts for $3.32 billion, and the Devices segment, contributing $579.97 million. The Platform segment is a significant driver of Roku’s business model.
Roku, navigating through a dynamic tech landscape, has demonstrated a strategic pivot with its recent partnership expansions and robust R&D focus. The company’s revenue surged to $1.06 billion in Q3 2024, up from $912 million the previous year, reflecting an 11.4% increase. This growth is underpinned by significant R&D investments totaling $300 million for the year, emphasizing Roku’s commitment to innovation in streaming technology and advertising solutions. Notably, the integration of FreeCast’s app on Roku’s platform showcases a forward-thinking approach to enhancing content accessibility and ad targeting precision—critical as Roku aims for profitability with projected annual earnings growth of 60.38%. These strategic moves could well position Roku within the competitive streaming space despite current unprofitability challenges.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Warner Music Group Corp. is a music entertainment company operating in the United States, the United Kingdom, Germany, and internationally, with a market cap of approximately $16.85 billion.
Operations: Warner Music Group generates revenue primarily from Recorded Music, which accounts for $5.22 billion, and Music Publishing, contributing $1.21 billion. The company’s operations span across multiple regions internationally beyond its core markets in the United States, the United Kingdom, and Germany.
Warner Music Group (WMG) is distinguishing itself in the competitive tech-driven music industry, with a strategic focus on high-growth markets like India and robust R&D investments. In 2024, WMG’s revenue increased to $6.43 billion, up from $6.04 billion the previous year, demonstrating a growth rate of 5.2%. Despite this modest increase, the company’s earnings are projected to surge by 20.8% annually over the next three years, underpinned by significant R&D spending that enhances its technological capabilities and market reach. Additionally, WMG has committed to a $100 million share repurchase program to boost shareholder value, signaling confidence in its financial health and future prospects.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:BPMC NasdaqGS:ROKU and NasdaqGS:WMG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Add Comment